Esperion to Host Analyst and Investor Day Event on May 30
May 07 2019 - 5:30AM
Esperion (NASDAQ:ESPR) today announced that the company will
host an analyst and investor day on Thursday, May 30, 2019,
beginning at 9:00 a.m. Eastern Time. The event will feature
presentations from members of the Esperion Lipid Management Team as
well as physician panels.
The live event will be videocast simultaneously and accessible
through the Events & Presentations page of the Esperion website
at investor.esperion.com. Access to the event replay will be
available approximately two hours after completion and will be
archived on the company's website for approximately 90 days.
Bempedoic Acid
Bempedoic acid is our lead, non-statin, complementary, orally
available, once-daily, LDL-C lowering therapy. With a targeted
mechanism of action, bempedoic acid is a first-in-class, ATP
Citrate Lyase (ACL) inhibitor that reduces cholesterol biosynthesis
and lowers LDL-C by up-regulating the LDL receptor. Similar to
statins, bempedoic acid also reduces hsCRP, a key marker of
inflammation associated with cardiovascular disease. Completed
Phase 3 studies conducted in more than 4,000 patients, with over
2,600 patients treated with bempedoic acid, have produced an
additional 18 percent LDL-C lowering when used with moderate- and
high-intensity statins and 28 percent LDL-C lowering when used with
no background statin.
Bempedoic Acid / Ezetimibe Combination
Tablet
Through the complementary mechanisms of action of inhibition of
cholesterol synthesis (bempedoic acid) and inhibition of
cholesterol absorption (ezetimibe), the bempedoic acid / ezetimibe
combination tablet is a non-statin, orally available, once-daily,
LDL-C lowering therapy. Inhibition of ATP Citrate Lyase (ACL) by
bempedoic acid reduces cholesterol biosynthesis and lowers LDL-C by
up-regulating the LDL receptor. Inhibition of Niemann-Pick C1-Like
1 (NPC1L1) by ezetimibe results in reduced absorption of
cholesterol from the gastrointestinal tract, thereby reducing
delivery of cholesterol to the liver, which in turn upregulates the
LDL receptors. Phase 3 data demonstrated that this combination
results in a 29 percent LDL-C lowering when used with maximally
tolerated statins, a 44 percent LDL-C lowering when used with no
background statin (post-hoc analysis), and a 34 percent reduction
in high sensitivity C-reactive protein (hsCRP).
CLEAR Outcomes
The effect of bempedoic acid on cardiovascular morbidity and
mortality has not yet been determined. Esperion initiated a global
cardiovascular outcomes trial (CVOT) to assess the effects of
bempedoic acid on the occurrence of major cardiovascular events in
patients with, or at high risk for, cardiovascular disease (CVD)
who are only able to tolerate less than the lowest approved daily
starting dose of a statin and considered "statin averse." The CVOT
— known as CLEAR Outcomes — is an event-driven, global, randomized,
double-blind, placebo-controlled study expected to enroll
approximately 12,600 patients with hypercholesterolemia and high
CVD risk at over 1,000 sites in approximately 30 countries.
Esperion's Commitment to Patients with
Hypercholesterolemia
High levels of LDL-C can lead to a build-up of fat and
cholesterol in and on artery walls (known as atherosclerosis),
potentially leading to cardiovascular events, including heart
attack or stroke. In the U.S., 96 million people, or more than 37
percent of the adult population, have elevated LDL-C. There are
approximately 18 million people in the U.S. with atherosclerotic
cardiovascular disease (ASCVD) who live with elevated levels of
LDL-C despite taking maximally tolerated lipid-modifying therapy —
including individuals considered statin averse — leaving them at
high risk for cardiovascular events. More than 50 percent of ASCVD
patients who are not able to reach their LDL-C goals with statins
alone need less than a 40 percent reduction to reach their LDL-C
threshold.
Esperion's mission as the Lipid Management Company is to deliver
once-daily, oral therapies that complement existing oral drugs to
provide the additional LDL-C lowering that these patients need.
The Lipid Management Company
Esperion is the Lipid Management Company passionately committed
to developing and commercializing complementary, cost-effective,
convenient, once-daily, oral therapies for the treatment of
patients with elevated LDL-C. Through scientific and clinical
excellence, and a deep understanding of cholesterol biology, the
experienced Lipid Management Team at Esperion is committed to
developing new LDL-C lowering therapies that will make a
substantial impact on reducing global cardiovascular disease, the
leading cause of death around the world. Bempedoic acid and the
bempedoic acid / ezetimibe combination tablet are targeted
therapies that have been shown to significantly lower elevated
LDL-C levels in patients with hypercholesterolemia, including
patients inadequately treated with current lipid-modifying
therapies. For more information, please visit www.esperion.com
and follow us on Twitter
at https://twitter.com/EsperionInc.
Investor Contact: Alex Schwartz Esperion
734-249-3386 aschwartz@esperion.com
Media Contact: Elliot Fox W2Opure 212-257-6724
efox@purecommunications.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Sep 2023 to Sep 2024